Raymond James Maintains Rating And Raises Price Target On Quidel Corporation (QDEL)


Quidel Corporation (NASDAQ:QDEL).

On September 19 Barclays held the company rating at “Overweight” but raised the price target to $45.00 from $39.00. On September 19 the stock rating was upgraded from “” to “Overweight” in an announcement from PiperJaffray.

July 27 investment analysts at Barclays held the stock rating at “Overweight” but moved up the price target from $22.00 to $39.00. On July 18, 2017 the stock rating was changed to “Outperform” by William Blair a boost from the previous “Market Perform” rating.

On July 18 the company was upgraded to “Buy” from “Hold” by Canaccord Genuity.

The company is trading up by 1.13%% since yesterday’s close of 43.55. It is currently trading at $44.04 which is quite a bit above the 50 day moving average which is $34.42 and much higher than the 200 day moving average of $27.83. The 50 day moving average went up $9.62 or +27.96% and the 200 day average went up $16.21 or +58.25%.

Quidel Corporation, launched on July 14, 1987, is involved in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. The Business’s diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain..

Short traders are more bearish on the company lately if you take a look at the uptick in short interest. The stock realized a rise in short interest of 0.81% between August 15, 2017 and August 31, 2017. Short interest grew 28,730 over that period. The days to cover increased to 15.0 and the short interest percentage is 0.11% as of August 31.